Viking Therapeutics

Clinical-stage biotech developing VK2735, a dual GLP-1/GIP receptor agonist for obesity/metabolic disease, in two forms — a weekly subcutaneous injection (Phase 3 VANQUISH-1/2, fully enrolled) and a daily oral tablet (Phase 3 initiation targeted Q4 2026). Earlier-stage: VK2809 (THR-β agonist, NASH/MASH), VK3019 (amylin agonist).

• monetization model: Clinical-stage biopharma; no product sales. Operations funded mainly by equity/debt; future value via licensing milestones/royalties and, if approved, product sales. 10-K Item 1, Item 7; EDGAR 10-K index: [sec.gov ; accession UNKNOWN]
• revenue mix: 100% pre-revenue; no product revenue disclosed; single reportable segment. 10-K Note on segments; 10-Q statements; EDGAR 10-Q index: [sec.gov ; accession UNKNOWN]
• who pays: Currently investors/equity markets; no commercial customer. Future: payers/insurers, providers, patients; potential pharma partners. [10-K Item 1/Risk Factors; accession UNKNOWN]
• margin_value_capture: Gross margin UNKNOWN (no sales); operating margin negative due to R&D; value accrues from pipeline IP/clinical data. [10-K Item 7; accession UNKNOWN]

• customer classes: Payers & Insurers, Health Systems & Providers, Consumers (D2C Healthspan), Pharma & Biotech [10-K Item 1/Risk Factors; accession UNKNOWN]

Viking Therapeutics, Inc.

Viking Therapeutics is a clinical-stage biopharmaceutical company. It does not have an approved commercial product. Its disclosed business purpose is the development of metabolic and endocrine therapies, with the lead programs directed at obesity and at MASH/NASH and dyslipidemia.

This structural fact is visible from the SEC EDGAR issuer directory, which shows a company filing as a development-stage biotechnology issuer. The company pages and pipeline descriptions confirm that VKTX’s model is preclinical/clinical development, not commercial sales.

VKTX has no current end-user monetization. The company must either:

1. Advance a drug candidate through clinical trials to approval and build or partner a commercial organization, or
2. License or sell the program to a larger pharmaceutical company in exchange for upfront, milestone, and royalty payments.

This is not a manufacturing, subscription, advertising, or transaction-fee business. The economic asset is intellectual property and clinical data.

The company funds itself through equity issuances. Public clinical-stage companies typically file S-3 shelf registrations, at-the-market offerings, and underwritten follow-on offerings. Any specific financing amounts, share counts, or dilution terms from those offerings are needs primary source validation and would be found in S-1/S-3/424B/8-K filings on EDGAR.

Gross margin is not meaningful because there is no product revenue.

Operating margin is negative and structurally likely to remain negative while development spending continues. But exact R&D expense, G&A expense, net loss, loss per share, and operating margin are needs primary source validation.

VKTX has no current commercial customers.

$0 revenue (pre-revenue). Q2 2026 net loss $128.0M ($1.10/sh); H1 2026 net loss $286.3M ($2.47/sh). Cash + short-term investments $501.7M at 06/30/26. Market cap ≈ $3.86B (116.26M shares × $33.19). (Sources: 10-Q 07/29/26; Twelve Data price.)

If VK2735 subQ clears Phase 3 with competitive efficacy/tolerability, Viking becomes the most credible independent pure-play acquisition target in the obesity franchise (LLY/NVO/AMGN all need oral + maintenance assets); the oral tablet is the differentiated "convenience" wedge. The thesis is a terminal M&A-optionality + franchise bet, not a self-commercializing one.

• Balance sheet (10-Q 06/30/26): cash $125.75M + ST investments $375.91M = $501.66M; total assets $521.9M; stockholders' equity $408.3M; accumulated deficit $1.134B (total capital consumed to date).
• P&L (10-Q): Q2 R&D $115.75M (vs $60.15M Q2'25, +92% YoY — Phase 3 ramp); H1 R&D $265.90M (vs $101.54M H1'25). Q2 net loss $128.02M; H1 net loss $286.35M. Weighted-average shares 116.26M (Q2), 115.92M (H1); anti-dilutive securities 7.83M (5.99M options + 1.81M RSUs).
• Financing (S-3ASR filed 07/30/26): $500M at-the-market (ATM) shelf via Stifel/Piper Sandler/Cantor/Oppenheimer/Canaccord — the dilution vehicle, filed one day after the 10-Q.
• Program state (X/company guidance): Phase 3 VANQUISH-1 and VANQUISH-2 fully enrolled (>4,600 pts reported); maintenance-study data expected Q3 2026 (Sept); oral Phase 3 initiation Q4 2026; Phase 3 topline mid-to-late Q3 2027.
• Prior efficacy: subQ VENTURE Phase 2 (13-wk, Feb 2024) ≈ 14.7% mean weight loss at 15mg (best-in-class 13-wk profile at the time); oral Phase 2 (13-wk, Aug 2025) ≈ 8–13% dose-dependent weight loss with ~97% ≥5% responders — solid but not best-in-class, triggering a ~30–40% sell-off vs. over-built "best-in-class" expectations.

1. Cash runway vs. catalyst timeline (THE binding constraint). H1 2026 net cash consumption = $705.74M (12/31/25 cash+inv) − $501.66M (06/30/26) = $204.08M over 6 months = $34.0M/month. Runway at that burn: $501.66M ÷ $34.0M ≈ 14.7 months → ~mid-2027. But burn is rising (oral Phase 3 initiation Q4'26 + full VANQUISH enrollment carry), so a realistic forward burn of ~$38–40M/mo compresses runway to ~12.5–13.2 months, i.e. cash reaches near-zero in late Q3/early Q4 2027 — exactly the Phase 3 topline window. Viking has enough to reach data with thin margin; any slip forces a pre-data raise.

1. Dilution math (cost-of-moat). $500M ATM ÷ $33.19 = 15.06M new shares = +12.9% on the 116.26M base (≈ +12.1% on ~124M fully diluted). This is the pre-data financing cost the equity must absorb before the value-inflecting readout.

1. Oral peptide bioavailability economics. Oral peptide bioavailability (SNAC-class permeation enhancers) is ~0.8–1% vs. ~70–80% for subcutaneous. An oral peptide therefore requires ~75–100× the API mass per absorbed dose of an injectable — the fundamental cost/complexity reason LLY's small-molecule orforglipron (no bioavailability penalty, cheap COGS) is the structural threat to Viking's oral wedge. (Source for BA: Novo/peer-reviewed SNAC literature — inferred; flag as derived.)

1. Valuation / cost-of-moat. EV = $3.86B market cap − $501.7M cash = $3.36B. Accumulated deficit $1.134B is the capital already spent building the franchise. Against a ~$100–150B obesity TAM, the defended prize at a modest ~5% share ($5–7.5B peak) implies a cost-of-moat ratio of ~15–23% ($1.13B ÷ $5–7.5B) — reasonable if the binary Phase 3 resolves positively, but the full $3.36B EV is currently paid in advance of any data.